{"id":"conventional-24-week-glucocorticoid-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (opportunistic or bacterial)"},{"rate":null,"effect":"Hyperglycemia / glucose intolerance"},{"rate":null,"effect":"Osteoporosis / bone loss"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Cushingoid features"},{"rate":null,"effect":"Mood disturbances / psychiatric effects"}]},"_chembl":{"chemblId":"CHEMBL2360841","moleculeType":"Small molecule","molecularWeight":"272.74"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Conventional glucocorticoid regimens work by activating intracellular glucocorticoid receptors, which translocate to the nucleus and modulate gene expression to reduce inflammation and immune cell activation. Over a 24-week treatment course, this leads to suppression of inflammatory mediators, reduced immune cell proliferation, and decreased vascular permeability. The regimen is typically used in conditions requiring sustained anti-inflammatory or immunosuppressive effects.","oneSentence":"Glucocorticoids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:31:13.431Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune conditions requiring sustained immunosuppression (specific indication not detailed in source)"}]},"trialDetails":[{"nctId":"NCT07151456","phase":"PHASE4","title":"Short-term gluCOCOrticoid in Adult STEROID-sensitive Nephrotic Syndrome: The COCO-ASTEROID Study","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2026-01","conditions":"Idiopathic Nephrotic Syndrome","enrollment":224}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Conventional 24-week glucocorticoid regimen","genericName":"Conventional 24-week glucocorticoid regimen","companyName":"First Affiliated Hospital of Wenzhou Medical University","companyId":"first-affiliated-hospital-of-wenzhou-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glucocorticoids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune conditions requiring sustained immunosuppression (specific indication not detailed in source).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}